AKT1 and cancer: In fact, AKTE17K mutation has been considered as a potential therapeutic target in cancers for several targeted therapies and inhibitors of the AKT signaling pathway like ARQ751 and ARQ092 [348,349,350], capivasertib or AZD5363 [351,352,353], and BAY1125976 [354], which are currently being developed and tested in clinical trials to specifically target and inhibit the downstream effects of this mutation.